Piper Sandler raised the firm’s price target on Ionis Pharmaceuticals to $63 from $62 and keeps an Overweight rating on the shares following quarterly results. The Q4 print itself was solid as total revenue of $325M easily beat consensus, and full year 2024 guidance largely aligned with expectations, Piper says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IONS:
- Ionis reports fourth quarter and full year 2023 financial results
- Ionis Pharmaceuticals sees FY24 revenue over $575M, consensus $636.36M
- Ionis Pharmaceuticals reports Q4 EPS (6c), consensus (83c)
- IONS Upcoming Earnings Report: What to Expect?
- Ionis Pharmaceuticals confirms FDA orphan designation for olezarsen
